Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus

Cara Therapeutics (CARA) PT Raised to $34 at Piper Jaffray

Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and bumped his price target on Cara Therapeutics (NASDAQ: CARA) to $34.00 (from $30.00) after the company announced positive results from its Phase II study of IV CR845 in Uremic Pruritus (UP), which achieved the primary endpoint... More

Cara Therapeutics (CARA) Fair Value Target Lifted to $27 at Janney Capital

Janney Capital analyst Chiara Russo raised her fair value target on Cara Therapeutics (NASDAQ: CARA) to $27.00 (from $25.00) announced positive top-line data this morning for IV CR845 in its Phase 2 Proof-of-Concept (POC) trial for dialysis itch, which hit statistical significance not just on the primary... More

Cara Therapeutics (CARA) PT Raised to $27 at Needham & Company

Needham & Company analyst Alan Carr reiterated a Buy rating and boosted his price target on Cara Therapeutics (NASDAQ: CARA) to $27.00 (from $22.00) following positive CR-845 results in Uremic Pruritus.

Carr commented, "Cara announced positive results from its Phase 2 trial of CR-845 in uremic... More

Cara Therapeutics (CARA) Announces Statistically Significant Results From Phase 2 Trial in Uremic Pruritus

Cara Therapeutics, Inc. (Nasdaq: CARA) today announced statistically significant topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP). Uremic pruritus is a chronic systemic itch condition in patients with renal failure, often receiving hemodialysis. There are currently no approved products in the United States for the condition.

"These results demonstrate the potential of our lead candidate CR845 to address an additional indication of significant unmet need beyond our lead I.V. CR845 program in acute pain," said... More